AI Scientists Are Only as Good as Their Evidence: A Stratified Ablation of Proprietary Data and Reasoning Skills in Drug-Asset Valuation
A new research paper explores the impact of data access on AI scientist performance in drug-asset valuation. The study found that while reasoning skills and tools improve calibration, proprietary data significantly increases the AI's ability to recover relevant information and make informed decisions. Without access to curated, proprietary datasets, AI performance is fundamentally capped, regardless of advanced reasoning capabilities. AI
IMPACT Highlights the critical role of proprietary data in unlocking advanced AI capabilities for specialized decision-making tasks.